3期试验-话题@MedSci

#3期试验#

46篇内容 | 2239人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1531328, encodeId=51681531328ed, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, objectTitle=Nat Med：阿维鲁单抗联合阿西替尼与舒尼替尼治疗晚期肾细胞癌:JAVELIN Renal 1013期试验生物标志物分析, objectType=article, longId=201119, objectId=02dd201119b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02dd201119b7, replyNumber=0, likeNumber=118, createdTime=2020-09-25, rootId=0, userName=zexyw05, userId=06eb12252541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02dd201119b7, moduleTitle=Nat Med：阿维鲁单抗联合阿西替尼与舒尼替尼治疗晚期肾细胞癌:JAVELIN Renal 1013期试验生物标志物分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02dd201119b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1531327, encodeId=0d81153132ea0, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, objectTitle=Lancet Neurology：口服Atogepant治疗成人发作性偏头痛的安全性、耐受性和有效性：一项双盲、随机2b/3期试验, objectType=article, longId=199902, objectId=ebc019990227, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ebc019990227, replyNumber=0, likeNumber=107, createdTime=2020-08-26, rootId=0, userName=zexyw05, userId=06eb12252541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ebc019990227, moduleTitle=Lancet Neurology：口服Atogepant治疗成人发作性偏头痛的安全性、耐受性和有效性：一项双盲、随机2b/3期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ebc019990227)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1531326, encodeId=4cf415313262a, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, objectTitle=Blood：3期试验：两组BTK抑制剂治疗华氏巨球蛋白血症！, objectType=article, longId=198977, objectId=96891989e774, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96891989e774, replyNumber=0, likeNumber=65, createdTime=2020-08-09, rootId=0, userName=zexyw05, userId=06eb12252541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96891989e774, moduleTitle=Blood：3期试验：两组BTK抑制剂治疗华氏巨球蛋白血症！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96891989e774)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1531325, encodeId=0e771531325c6, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, objectTitle=凌腾医药开展双特异性抗体用于胃癌全球临床3期试验, objectType=article, longId=197578, objectId=232d19e5785e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=232d19e5785e, replyNumber=0, likeNumber=66, createdTime=2020-07-17, rootId=0, userName=zexyw05, userId=06eb12252541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=232d19e5785e, moduleTitle=凌腾医药开展双特异性抗体用于胃癌全球临床3期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=232d19e5785e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1531324, encodeId=c10a1531324da, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, objectTitle=Moderna将于7月开始，开展其新冠病毒COVID-19疫苗的关键3期试验, objectType=article, longId=195328, objectId=f30519532868, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f30519532868, replyNumber=0, likeNumber=79, createdTime=2020-06-06, rootId=0, userName=zexyw05, userId=06eb12252541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f30519532868, moduleTitle=Moderna将于7月开始，开展其新冠病毒COVID-19疫苗的关键3期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f30519532868)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1531323, encodeId=7ef315313239a, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, objectTitle=Lancet oncol：3期试验：UGN-101输尿管灌注治疗上尿路移行细胞癌癌的安全性和疗效, objectType=article, longId=193391, objectId=3c4019339127, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c4019339127, replyNumber=0, likeNumber=69, createdTime=2020-05-04, rootId=0, userName=zexyw05, userId=06eb12252541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c4019339127, moduleTitle=Lancet oncol：3期试验：UGN-101输尿管灌注治疗上尿路移行细胞癌癌的安全性和疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c4019339127)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1531322, encodeId=cd4f1531322e8, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, objectTitle=Lancet haematol：3期试验：达雷木单抗皮下注射和静脉注射治疗复发性/难治性多发性骨髓瘤的效果和安全性对比, objectType=article, longId=192943, objectId=28a119294391, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28a119294391, replyNumber=0, likeNumber=42, createdTime=2020-04-26, rootId=0, userName=zexyw05, userId=06eb12252541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28a119294391, moduleTitle=Lancet haematol：3期试验：达雷木单抗皮下注射和静脉注射治疗复发性/难治性多发性骨髓瘤的效果和安全性对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28a119294391)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1531321, encodeId=239a1531321b6, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, objectTitle=Lancet oncol：3期试验：卡铂-聚乙醇化脂质体多柔比星-贝伐珠单抗治疗铂敏感性复发性卵巢癌的疗效, objectType=article, longId=192935, objectId=dc37192935a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc37192935a7, replyNumber=0, likeNumber=35, createdTime=2020-04-26, rootId=0, userName=zexyw05, userId=06eb12252541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc37192935a7, moduleTitle=Lancet oncol：3期试验：卡铂-聚乙醇化脂质体多柔比星-贝伐珠单抗治疗铂敏感性复发性卵巢癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc37192935a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1531320, encodeId=3ccf1531320ac, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, objectTitle=CheckMate-743试验中期分析显示：纳武利尤单抗联合伊匹木单抗治疗恶性胸膜间皮瘤3期试验达主要终点, objectType=article, longId=192692, objectId=46461926922a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46461926922a, replyNumber=0, likeNumber=154, createdTime=2020-04-23, rootId=0, userName=zexyw05, userId=06eb12252541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46461926922a, moduleTitle=CheckMate-743试验中期分析显示：纳武利尤单抗联合伊匹木单抗治疗恶性胸膜间皮瘤3期试验达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46461926922a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1531319, encodeId=de1815313199a, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, objectTitle=百济神州宣布，抗PD-1单抗替雷利珠单抗联合化疗用于非鳞状非小细胞肺癌患者，3期试验达到无进展生存的主要终点, objectType=article, longId=192235, objectId=15911922351b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15911922351b, replyNumber=0, likeNumber=95, createdTime=2020-04-16, rootId=0, userName=zexyw05, userId=06eb12252541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15911922351b, moduleTitle=百济神州宣布，抗PD-1单抗替雷利珠单抗联合化疗用于非鳞状非小细胞肺癌患者，3期试验达到无进展生存的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15911922351b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1531318, encodeId=33f31531318d7, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, objectTitle=Lancet oncol：3期试验：FOLFOXIRI+贝伐珠单抗预治疗/再治疗转移性结直肠癌的效果优于mFOLFOX6+贝伐单抗/FOLFIRI+贝伐单抗, objectType=article, longId=190232, objectId=9131190232f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9131190232f7, replyNumber=0, likeNumber=72, createdTime=2020-03-19, rootId=0, userName=zexyw05, userId=06eb12252541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9131190232f7, moduleTitle=Lancet oncol：3期试验：FOLFOXIRI+贝伐珠单抗预治疗/再治疗转移性结直肠癌的效果优于mFOLFOX6+贝伐单抗/FOLFIRI+贝伐单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9131190232f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1531317, encodeId=d235153131e59, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, objectTitle=Novan报告了SB206针对接触传染性软疣的3期试验疗效结果, objectType=article, longId=185648, objectId=e30f1856489f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e30f1856489f, replyNumber=0, likeNumber=57, createdTime=2020-01-05, rootId=0, userName=zexyw05, userId=06eb12252541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e30f1856489f, moduleTitle=Novan报告了SB206针对接触传染性软疣的3期试验疗效结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e30f1856489f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1531316, encodeId=0fd91531316ca, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, objectTitle=Lancet haemat：3期试验：利伐沙班治疗静脉血栓栓塞儿童的临床预后和安全性, objectType=article, longId=182776, objectId=6513182e7613, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6513182e7613, replyNumber=0, likeNumber=70, createdTime=2019-11-11, rootId=0, userName=zexyw05, userId=06eb12252541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6513182e7613, moduleTitle=Lancet haemat：3期试验：利伐沙班治疗静脉血栓栓塞儿童的临床预后和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6513182e7613)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1531315, encodeId=d7bb153131583, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, objectTitle=ERYTECH的红细胞包裹药物eryaspase在二线胰腺癌的3期试验中取得里程碑, objectType=article, longId=182394, objectId=c8ca182394a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8ca182394a4, replyNumber=0, likeNumber=60, createdTime=2019-11-06, rootId=0, userName=zexyw05, userId=06eb12252541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8ca182394a4, moduleTitle=ERYTECH的红细胞包裹药物eryaspase在二线胰腺癌的3期试验中取得里程碑, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8ca182394a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1531314, encodeId=cdff153131477, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, objectTitle=Lancet oncol：3期试验：度伐单抗治疗III期非小细胞肺癌, objectType=article, longId=180827, objectId=7c0318082ec2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c0318082ec2, replyNumber=0, likeNumber=57, createdTime=2019-10-11, rootId=0, userName=zexyw05, userId=06eb12252541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c0318082ec2, moduleTitle=Lancet oncol：3期试验：度伐单抗治疗III期非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c0318082ec2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1531313, encodeId=e4c41531313b6, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, objectTitle=Arthritis Rheumatol：Upadacitinib治疗甲氨蝶呤反应不足类风湿性关节炎的3期试验, objectType=article, longId=175230, objectId=0b961e52306e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b961e52306e, replyNumber=0, likeNumber=71, createdTime=2019-07-13, rootId=0, userName=zexyw05, userId=06eb12252541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b961e52306e, moduleTitle=Arthritis Rheumatol：Upadacitinib治疗甲氨蝶呤反应不足类风湿性关节炎的3期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b961e52306e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1531312, encodeId=627e15313127f, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, objectTitle=礼来IL-23抑制剂治疗克罗恩病2期结果积极，今年启动3期试验, objectType=article, longId=166678, objectId=b3b81666e8fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3b81666e8fb, replyNumber=0, likeNumber=151, createdTime=2019-05-25, rootId=0, userName=zexyw05, userId=06eb12252541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3b81666e8fb, moduleTitle=礼来IL-23抑制剂治疗克罗恩病2期结果积极，今年启动3期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3b81666e8fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1531311, encodeId=d79b153131127, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, objectTitle=MorphoSys宣布开始3期试验（PROTOSTAR）评估IL-23单抗Guselkumab对银屑病儿童患者的疗效, objectType=article, longId=149686, objectId=d1891496860a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1891496860a, replyNumber=0, likeNumber=100, createdTime=2018-09-28, rootId=0, userName=zexyw05, userId=06eb12252541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1891496860a, moduleTitle=MorphoSys宣布开始3期试验（PROTOSTAR）评估IL-23单抗Guselkumab对银屑病儿童患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1891496860a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1531310, encodeId=10821531310dd, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, objectTitle=百济神州启动PD-1抗体联合化疗治疗非小细胞肺癌的临床3期试验, objectType=article, longId=146648, objectId=02c614664864, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02c614664864, replyNumber=0, likeNumber=66, createdTime=2018-08-16, rootId=0, userName=zexyw05, userId=06eb12252541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02c614664864, moduleTitle=百济神州启动PD-1抗体联合化疗治疗非小细胞肺癌的临床3期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02c614664864)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1531309, encodeId=8a50153130933, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, objectTitle=Lancet respir med：临床3期试验：Tralokinumab，抗白介素13单克隆抗体，用于重度哮喘发作的效果和安全性评估, objectType=article, longId=138764, objectId=dc65138e6490, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc65138e6490, replyNumber=0, likeNumber=62, createdTime=2018-05-23, rootId=0, userName=zexyw05, userId=06eb12252541, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc65138e6490, moduleTitle=Lancet respir med：临床3期试验：Tralokinumab，抗白介素13单克隆抗体，用于重度哮喘发作的效果和安全性评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc65138e6490)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

3期试验

2020-05-29

zexyw05 (审核中...)

前往app查看评论内容

#3期试验#

Nat Med：阿维鲁单抗联合阿西替尼与舒尼替尼治疗晚期肾细胞癌:JAVELIN Renal 1013期试验生物标志物分析

2020-09-25

zexyw05 (审核中...)

前往app查看评论内容

#3期试验#

Lancet Neurology：口服Atogepant治疗成人发作性偏头痛的安全性、耐受性和有效性：一项双盲、随机2b/3期试验

2020-08-26

zexyw05 (审核中...)

前往app查看评论内容

#3期试验#

Blood：3期试验：两组BTK抑制剂治疗华氏巨球蛋白血症！

2020-08-09

zexyw05 (审核中...)

前往app查看评论内容

#3期试验#

凌腾医药开展双特异性抗体用于胃癌全球临床3期试验

2020-07-17

zexyw05 (审核中...)

前往app查看评论内容

#3期试验#

Moderna将于7月开始，开展其新冠病毒COVID-19疫苗的关键3期试验

2020-06-06

zexyw05 (审核中...)

前往app查看评论内容

#3期试验#

Lancet oncol：3期试验：UGN-101输尿管灌注治疗上尿路移行细胞癌癌的安全性和疗效

2020-05-04

zexyw05 (审核中...)

前往app查看评论内容

#3期试验#

Lancet haematol：3期试验：达雷木单抗皮下注射和静脉注射治疗复发性/难治性多发性骨髓瘤的效果和安全性对比

2020-04-26

zexyw05 (审核中...)

前往app查看评论内容

#3期试验#

Lancet oncol：3期试验：卡铂-聚乙醇化脂质体多柔比星-贝伐珠单抗治疗铂敏感性复发性卵巢癌的疗效

2020-04-26

zexyw05 (审核中...)

前往app查看评论内容

#3期试验#

CheckMate-743试验中期分析显示：纳武利尤单抗联合伊匹木单抗治疗恶性胸膜间皮瘤3期试验达主要终点

2020-04-23

zexyw05 (审核中...)

前往app查看评论内容

#3期试验#

百济神州宣布，抗PD-1单抗替雷利珠单抗联合化疗用于非鳞状非小细胞肺癌患者，3期试验达到无进展生存的主要终点

2020-04-16

zexyw05 (审核中...)

前往app查看评论内容

#3期试验#

Lancet oncol：3期试验：FOLFOXIRI+贝伐珠单抗预治疗/再治疗转移性结直肠癌的效果优于mFOLFOX6+贝伐单抗/FOLFIRI+贝伐单抗

2020-03-19

zexyw05 (审核中...)

前往app查看评论内容

#3期试验#

Novan报告了SB206针对接触传染性软疣的3期试验疗效结果

2020-01-05

zexyw05 (审核中...)

前往app查看评论内容

#3期试验#

Lancet haemat：3期试验：利伐沙班治疗静脉血栓栓塞儿童的临床预后和安全性

2019-11-11

zexyw05 (审核中...)

前往app查看评论内容

#3期试验#

ERYTECH的红细胞包裹药物eryaspase在二线胰腺癌的3期试验中取得里程碑

2019-11-06

zexyw05 (审核中...)

前往app查看评论内容

#3期试验#

Lancet oncol：3期试验：度伐单抗治疗III期非小细胞肺癌

2019-10-11

zexyw05 (审核中...)

前往app查看评论内容

#3期试验#

Arthritis Rheumatol：Upadacitinib治疗甲氨蝶呤反应不足类风湿性关节炎的3期试验

2019-07-13

zexyw05 (审核中...)

前往app查看评论内容

#3期试验#

礼来IL-23抑制剂治疗克罗恩病2期结果积极，今年启动3期试验

2019-05-25

zexyw05 (审核中...)

前往app查看评论内容

#3期试验#

MorphoSys宣布开始3期试验（PROTOSTAR）评估IL-23单抗Guselkumab对银屑病儿童患者的疗效

2018-09-28

zexyw05 (审核中...)

前往app查看评论内容

#3期试验#

百济神州启动PD-1抗体联合化疗治疗非小细胞肺癌的临床3期试验

2018-08-16

zexyw05 (审核中...)

前往app查看评论内容

#3期试验#

Lancet respir med：临床3期试验：Tralokinumab，抗白介素13单克隆抗体，用于重度哮喘发作的效果和安全性评估

2018-05-23

科室
- - 订阅+
  - 更多科室
工具
服务